Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Cannabidiol regulates the expression of hypothalamus-pituitary-adrenal axis-related genes in response to acute restraint stress.

Viudez-Martínez A, García-Gutiérrez MS, Manzanares J.

J Psychopharmacol. 2018 Dec;32(12):1379-1384. doi: 10.1177/0269881118805495. Epub 2018 Oct 16.

PMID:
30324842
2.

Review of the neurological benefits of phytocannabinoids.

Maroon J, Bost J.

Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18. eCollection 2018. Review.

3.

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.

Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M.

Psychopharmacology (Berl). 2018 Jul;235(7):1923-1932. doi: 10.1007/s00213-018-4885-9. Epub 2018 Apr 5.

PMID:
29619533
4.

Drug-drug interactions as a result of co-administering Δ9-THC and CBD with other psychotropic agents.

Rong C, Carmona NE, Lee YL, Ragguett RM, Pan Z, Rosenblat JD, Subramaniapillai M, Shekotikhina M, Almatham F, Alageel A, Mansur R, Ho RC, McIntyre RS.

Expert Opin Drug Saf. 2018 Jan;17(1):51-54. doi: 10.1080/14740338.2017.1397128. Epub 2017 Oct 31. Review.

PMID:
29082802
5.

Cannabidiol in medical marijuana: Research vistas and potential opportunities.

Rong C, Lee Y, Carmona NE, Cha DS, Ragguett RM, Rosenblat JD, Mansur RB, Ho RC, McIntyre RS.

Pharmacol Res. 2017 Jul;121:213-218. doi: 10.1016/j.phrs.2017.05.005. Epub 2017 May 10. Review.

PMID:
28501518
6.

Targeting the Endocannabinoid System in Psychiatric Illness.

Katzman MA, Furtado M, Anand L.

J Clin Psychopharmacol. 2016 Dec;36(6):691-703. Review.

PMID:
27811555
7.

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.

Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, Mechoulam R, Guimarães FS.

PLoS One. 2016 Jul 14;11(7):e0158779. doi: 10.1371/journal.pone.0158779. eCollection 2016. Erratum in: PLoS One. 2016;11(8):e0162087.

8.

Prohedonic Effect of Cannabidiol in a Rat Model of Depression.

Shoval G, Shbiro L, Hershkovitz L, Hazut N, Zalsman G, Mechoulam R, Weller A.

Neuropsychobiology. 2016;73(2):123-9. doi: 10.1159/000443890. Epub 2016 Mar 25.

PMID:
27010632
9.

Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.

Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á.

Neuropharmacology. 2016 Apr;103:16-26. doi: 10.1016/j.neuropharm.2015.12.017. Epub 2015 Dec 19.

PMID:
26711860
10.

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.

de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS, Machado S, Arias-Carrión O, Crippa JA, Zuardi AW, Nardi AE, Silva AC.

CNS Neurol Disord Drug Targets. 2014;13(6):953-60. Review.

PMID:
24923339
11.

Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain.

Valvassori SS, Bavaresco DV, Scaini G, Varela RB, Streck EL, Chagas MH, Hallak JE, Zuardi AW, Crippa JA, Quevedo J.

Braz J Psychiatr. 2013 Oct-Dec;35(4):380-6. doi: 10.1590/1516-4446-2012-0886. Epub 2013 Dec 23.

12.

Endocannabinoid system and mood disorders: priming a target for new therapies.

Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F.

Pharmacol Ther. 2013 Apr;138(1):18-37. doi: 10.1016/j.pharmthera.2012.12.002. Epub 2012 Dec 20. Review.

PMID:
23261685
13.

Endocannabinoid system dysfunction in mood and related disorders.

Ashton CH, Moore PB.

Acta Psychiatr Scand. 2011 Oct;124(4):250-61. doi: 10.1111/j.1600-0447.2011.01687.x. Epub 2011 Mar 9. Review.

PMID:
21916860
14.

The endocannabinoid system in the regulation of emotions throughout lifespan: a discussion on therapeutic perspectives.

Marco EM, Laviola G.

J Psychopharmacol. 2012 Jan;26(1):150-63. doi: 10.1177/0269881111408459. Epub 2011 Jun 21. Review.

PMID:
21693551
15.

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JE, Zuardi AW, Crippa JA.

Neuropsychopharmacology. 2011 May;36(6):1219-26. doi: 10.1038/npp.2011.6. Epub 2011 Feb 9.

16.

The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism.

Jenny M, Schröcksnadel S, Überall F, Fuchs D.

Pharmaceuticals (Basel). 2010 Aug 13;3(8):2647-2660. Review.

17.

The endocannabinoid system and psychiatric disorders.

Parolaro D, Realini N, Vigano D, Guidali C, Rubino T.

Exp Neurol. 2010 Jul;224(1):3-14. doi: 10.1016/j.expneurol.2010.03.018. Epub 2010 Mar 29. Review.

PMID:
20353783
18.

Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.

Valvassori SS, Elias G, de Souza B, Petronilho F, Dal-Pizzol F, Kapczinski F, Trzesniak C, Tumas V, Dursun S, Chagas MH, Hallak JE, Zuardi AW, Quevedo J, Crippa JA.

J Psychopharmacol. 2011 Feb;25(2):274-80. doi: 10.1177/0269881109106925. Epub 2009 Nov 25.

PMID:
19939866
19.

Cannabinoids.

Grotenhermen F.

Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):507-30. Review.

PMID:
16266285
20.

Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.

Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C.

Anaesthesia. 2004 May;59(5):440-52.

Supplemental Content

Loading ...
Support Center